# Vera kidney drug Trutakna shows strong final results in Phase 3 trial

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-16 07:29 UTC · Category: Business · Sources: 8 · Current Velocity: 5.66

## Key People, Organizations & Locations
Phase, Trutakna, Vera

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Fierce Pharma | Vera’s strong phase 3 IgAN data for Trutakna intensify kidney disease rivalry | 2026-09-15 10:53 | [Source Link](https://news.google.com/rss/articles/CBMitAFBVV95cUxNNzMwZDhDVFFFYUg3T2pLUXVyUTV2bHU3WUl3S1hRR2w1Nm1VeVhqdmtLWUd4aXJNM1JqU0kza0t1eHJNSnhoLVZCbG1UUGJJUFFUa3pvcTI5N3REN3J3bHl6aXZaRS0xc3hQd3V0T1kwZ256aWV1Z1pzd24zUHQzbVp1NzRoV0NiZjZxZTFuWkNNTEZ3U0llWDVuUG1hVnZrQ3J1RFBRQ3F3SmgtUUo1MkNXZnM?oc=5) |
| Pulse 2.0 | Vera Therapeutics Reports Positive Two-Year Phase 3 Trutakna Results | 2026-09-15 10:53 | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxPOEdxRm9mRlhNcUlPS3o0czJCczF3WkRNQ2NnNGI3dE1EdUhKY0dPbXdIVGNoQkhJajRSZm5rS2p4VmpaUW1Sc2FDeF94TUtXMms2NDNqVUU0cVBzWGlqNHZqODk4QUczZEVNTTU4dFBxOGVJQWlNRHlOVk9XQnk2c0NQRllQN0lsXzAxd0xIdXR4QdIBlwFBVV95cUxNVmJBZGI5RGpuZDhrLWU2elMxUjlaWlRkZlphZWJSV0VkdFpRUklWRl9CN0I1YWlvakNrTmM4UFRLRkoybmxJeWxnT251ZFl4M1A5WnFhZF9WTjBoQlJ1SUZjbUFnQk9nX2c4X01xWE44ZTRoUlJBSVB1eFNSS2VFbFl6dVlrUUhRc3VjaTJOU2pzMW1fQUF3?oc=5) |
| marketscreener.com | Vera Therapeutics Announces TRUTAKNA Stabilized eGFR and Prevented Kidney Disease Progression through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | 2026-09-15 10:53 | [Source Link](https://news.google.com/rss/articles/CBMi6AFBVV95cUxOSzdOeWJlMWQ3S2IyZGZfbjdsMFItY1VJMk1UZEwtbngxU0hmRWIwbFVNXzlmX3gzanhJQWZsRFJia2cwb0NQeXhWU2NycHN4MFptcVpnYXZLQmxQYjkyQm1BUHVGbFVSWnA4dmp2WS1HLWFfc19CS3M1NUFfZ3lBVVJCTmdlcHVOVmQzQlFIemJxbXNVY0dnUmZ6Mkp0ZEpWRGlsOEt5TURYSEVlcTctb0ZMOTVidzRFZzRSWkJHdzVvWl9MTHh0Q0JRNGk4X1dyR1RUZ0s2ZGRrZFRLMjZOdWp4QmNHT1c0?oc=5) |
| HCPLive | Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data | 2026-09-15 10:53 | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxObGQ0MkdIbVB0RW9hUzBEbjBhMHpvMmVrMVhFeVhOeDJGU1ZaQzdPVEozMzBFLXBRWndiVURWR1NSR2l5RmwydVd0eEJ0b0FKSlo5ZkRwOGFNUU93NEgzQ3gxakFKRVVxdmZPMFBaMlhWQUpNS210OUZkM2liYVNDaVllbW5TeXFKTzdxUkU2ekR4NG5vOWc?oc=5) |
| Investor's Business Daily | Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens | 2026-09-15 10:53 | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxPRE1TZjZIUWFuQkNvelZEYzdRMDRLakJsQUx1WDEyaWxnQjFYWGZqOHM2MXZxN1NkbEFTXzJMa0FuN2llNlZ2TmhxOGhQSHNDSnI1Q1VsUjRZR21pY2ZOLVFxSTNtcVp1ZWI5WFIxSmlIanFsUkNVbEpYT0Jwd0VlRXctQ3pSODRFMU95ZWQtTGxSSlZNeFhsRWRR?oc=5) |
| Yahoo Finance | Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | 2026-09-15 10:53 | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxOY2RxUWlUME93bUJxMUhfOUo2c0xGWG0zWFlnTHBpUFdPUW5ncDkxcUlPSENZc1dfbUdSM2xwVzZWV2hwMVRiRUx1OWVxUmZ0SVUxVlhrQ0c2d2pLbTE1UU5jeDBuOGZUUlJRbnFpVl9qWHIzN3RCTjREdUlKaVpPN1Rhb00zMEYwZGw4SVJzdXVCQWdoYUh6UnNyZE9UM1o5Zk5wNllycU5oZFU?oc=5) |
| FirstWord Pharma | Positive data positions Vera's IgA nephropathy drug Trutakna for full approval | 2026-09-15 10:53 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE1uQllTQ0hXNGpCeHZyQk1DWUphRm9UaVBmQXhUZkZhVTJQSWhRaDM5eTllWW9Yc1lrR3VxbE5FdGN3SzlLWlRieUVvN05TRWNSWlRZ?oc=5) |
| STAT | Vera kidney drug Trutakna shows strong final results in Phase 3 trial | 2026-09-15 10:53 | [Source Link](https://news.google.com/rss/articles/CBMinAFBVV95cUxPMjZkcjd1dWkxUVdlSjNJU0M2OFhSeVJ4WEJXeHNrd1QxMlUxUFh1U3NFeDhib3l5ejdpa2pHTW1qRkZnOWQzSHpEMVVrNVprT1FUaTRoN2NRdzRHTmZudEFsU0xUVHlTU1RLX29vMnFCWWZnejZTVXlaQjFXWTVRVEdfbXJ5QTVDSnlsQ28zWldsMldFUF9fY1Vlcmg?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-16/vera-kidney-drug-trutakna-shows-strong-final-results-in-phase-3-trial*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*